Pfizer Ophthalmics and Bausch & Lomb Announce Co-Promotion Agreement Covering Xalatan, Alrex, Lotemax and Zylet

March 4, 2009

Pfizer Inc and Bausch & Lomb announced a co-promotion agreement involving both companies’ prescription ophthalmic pharmaceuticals in the United States. The agreement will allow both companies to greatly increase the level of eye care industry support for these important medications that treat serious ophthalmic conditions.The five-year agreement includes Pfizer’s Xalatan® (latanoprost ophthalmic solution) and Bausch & Lomb’s Alrex® (loteprednol etabonate ophthalmic suspension 0.2%), Lotemax® (loteprednol etabonate ophthalmic suspension 0.5%) and Zylet® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension).

The co-promotion agreement also will apply to Bausch & Lomb’s investigational anti-infective eye drop, besifloxacin ophthalmic suspension, 0.6%, which is currently under review by the U.S. Food and Drug Administration (FDA).

Under the terms of the agreement, both the Pfizer and Bausch & Lomb sales forces will promote Xalatan, Alrex, Lotemax, Zylet and besifloxacin (subject to FDA approval).

Read the full release.

 

 



Comments

Jump down to form below to submit your own comments

Trackback URL
http://eyedocnews.com/00699-pfizer-ophthalmics-and-bausch-lomb-announce-co-promotion-agreement-covering-xalatan-alrex-lotemax-and-zylet/trackback/

Have insights to contribute? Please submit your comment below